secwatch.observer — SEC 8-K summary
======================================

Issuer:     GeoVax Labs, Inc. (GOVX)
CIK:        0000832489
Form:       8-K
Filed at:   2024-08-07T23:59:59+00:00
Accession:  0001437749-24-025175
Event type: earnings
Sentiment:  positive
Materiality: 0.85
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

GeoVax reports Q2 net loss of $5.1M; awarded up to $388M BARDA contract for COVID vaccine trial
--------------------------------------------------------------------------------

- Net loss $5.1M ($1.99/share) vs $5.9M ($3.79) in Q2 2023; R&D expenses $4.3M.
- BARDA Project NextGen award for GEO-CM04S1 Phase 2b trial; total value $367-388M incl. Allucent.
- Cash $1.56M at June 30, 2024, down from $6.45M at Dec 31, 2023.
- Gedeptin advanced to expanded Phase 2 trial for head and neck cancer; activation H1 2025.
- Commercial manufacturing platform for GEO-CM04S1 established with Oxford Biomedica.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/832489/000143774924025175/0001437749-24-025175-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/832489/000143774924025175/govx20240806_8k.htm
  HTML page:      https://secwatch.observer/filing/0001437749-24-025175

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer